TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Genscript Biotech ( (HK:1548) ).
Legend Biotech, an associate of Genscript Biotech, will present new data on CARVYKTI, a treatment for multiple myeloma, at the 2025 ASCO and EHA annual meetings. This announcement highlights the ongoing development efforts in the CARTITUDE Clinical Development Program, which could have significant implications for the treatment of multiple myeloma and potentially enhance Legend Biotech’s position in the biotech industry.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, focusing on biotechnology and life sciences. The company is associated with Legend Biotech Corporation, which is involved in developing innovative therapies for patients, particularly in the area of multiple myeloma.
Average Trading Volume: 18,446,448
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$22.51B
Learn more about 1548 stock on TipRanks’ Stock Analysis page.